Restoring Mobility for a Better Quality of Life

We are committed to bring first-in-class breakthrough therapies to patients suffering from osteoarthritis in the world.

About Us

4Moving Biotech is a cutting-edge clinical-stage company pioneering in the field of osteoarthritis (OA) research. We were inspired by the groundbreaking work of renowned rheumatologist Prof. Francis Berenbaum; our unique product, 4P004, targets low-grade inflammation using GLP-1 analogs. This innovative application of GLP-1 analogs represents a promising path toward a natural curse of the disease. By integrating advanced AI, real-world data, and innovative clinical trial design, we optimize our Phase 2 trial selection using data from 11.4 million patients, swiftly advancing treatments to those who need them most

Scientific Foundations

4P004: Revolutionizing Osteoarthritis Treatment

A Paradigm Shift in Osteoarthritis Treatment With the introduction of 4P004, we target a transformative impact on osteoarthritis, altering the disease’s natural course, symptoms, and joint structural integrity.

Scientific Breakthrough

Our innovative therapy provides a comprehensive solution, targeting not just symptoms but the entire joint structure—cartilage, subchondral bone, and synovium. This approach represents a significant leap in managing osteoarthritis, with potential to modify its progression.

Regulatory and Trial Innovations

4P004 is at the forefront of regulatory science with its use of in-silico trials and AI-driven patient selection strategies, accelerating the path to clinical application. These advanced methodologies enable us to efficiently navigate the regulatory landscape and optimize trial outcomes.

Modifying OA’s Natural Progression

4P004 offers a unique approach to managing the disease’s natural course. By altering key biological pathways, it aims to provide lasting improvements in joint health and patient mobility.

Therapeutic Approach

4P004: Our solution milestones

4P004

Preclinical
Phase 1
POC Phase 2A
Pivotal Phase 2B

POC Phase 2A

Summary:

Following promising preclinical data that showcased a drug with both analgesic effects and structural benefits across joint tissues, we successfully completed a Phase 1 study to evaluate the safety and tolerability of 4P004 in osteoarthritis patients. Utilizing AI technology and insights from 11.4 million patients, we conducted an in-silico trial to identify the best responders, streamlining our participant selection for the Phase 2a Proof of Concept study. This next phase aims to demonstrate key efficacy endpoints, advancing our commitment to revolutionizing osteoarthritis treatment.